Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
New Oriental director Zhou Chenggang sells $3.97 million in common shares

New Oriental director Zhou Chenggang sells $3.97 million in common shares

ReutersReuters2026/08/11 10:18
  • New Oriental Education’s director Zhou Chenggang sold 70,000 ADS in two transactions on Aug. 7-10.
  • Sales priced at USD 56.32 per ADS on Aug. 7, USD 56.83 per ADS on Aug. 10.
  • Beneficial ownership fell to 429,998 ADS following the Aug. 10 sale.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Oriental Education & Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001998544-26-000006), on August 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well